232 related articles for article (PubMed ID: 9735103)
1. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
Lin S; Thomas M; Shlaes DM; Rudin SD; Knox JR; Anderson V; Bonomo RA
Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
[TBL] [Abstract][Full Text] [Related]
2. OHIO-1 beta-lactamase mutants: the Arg244Ser mutant and resistance to beta-lactams and beta-lactamase inhibitors.
Lin S; Thomas M; Mark S; Anderson V; Bonomo RA
Biochim Biophys Acta; 1999 Jun; 1432(1):125-36. PubMed ID: 10366735
[TBL] [Abstract][Full Text] [Related]
3. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
Thomson JM; Distler AM; Bonomo RA
Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
[TBL] [Abstract][Full Text] [Related]
4. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations.
Bonomo RA; Knox JR; Rudin SD; Shlaes DM
Antimicrob Agents Chemother; 1997 Sep; 41(9):1940-3. PubMed ID: 9303389
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
Papp-Wallace KM; Bethel CR; Distler AM; Kasuboski C; Taracila M; Bonomo RA
Antimicrob Agents Chemother; 2010 Feb; 54(2):890-7. PubMed ID: 20008772
[TBL] [Abstract][Full Text] [Related]
7. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
[TBL] [Abstract][Full Text] [Related]
8. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Bonomo RA; Rudin SA; Shlaes DM
FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
Therrien C; Kotra LP; Sanschagrin F; Mobashery S; Levesque RC
FEBS Lett; 2000 Mar; 470(3):285-92. PubMed ID: 10745083
[TBL] [Abstract][Full Text] [Related]
10. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R
FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544
[TBL] [Abstract][Full Text] [Related]
11. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
Kalp M; Totir MA; Buynak JD; Carey PR
J Am Chem Soc; 2009 Feb; 131(6):2338-47. PubMed ID: 19161282
[TBL] [Abstract][Full Text] [Related]
12. Complementary roles of mutations at positions 69 and 242 in a class A beta-lactamase.
Bonomo RA; Dawes CG; Knox JR; Shlaes DM
Biochim Biophys Acta; 1995 Feb; 1247(1):113-20. PubMed ID: 7873579
[TBL] [Abstract][Full Text] [Related]
13. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
[TBL] [Abstract][Full Text] [Related]
14. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
Padayatti PS; Helfand MS; Totir MA; Carey MP; Carey PR; Bonomo RA; van den Akker F
J Biol Chem; 2005 Oct; 280(41):34900-7. PubMed ID: 16055923
[TBL] [Abstract][Full Text] [Related]
15. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Papp-Wallace KM; Taracila M; Hornick JM; Hujer AM; Hujer KM; Distler AM; Endimiani A; Bonomo RA
Antimicrob Agents Chemother; 2010 Jul; 54(7):2867-77. PubMed ID: 20421396
[TBL] [Abstract][Full Text] [Related]
16. beta-Lactamase mutations far from the active site influence inhibitor binding.
Bonomo RA; Dawes CG; Knox JR; Shlaes DM
Biochim Biophys Acta; 1995 Feb; 1247(1):121-5. PubMed ID: 7873581
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases.
Sabbagh Y; Thériault E; Sanschagrin F; Voyer N; Palzkill T; Levesque RC
Antimicrob Agents Chemother; 1998 Sep; 42(9):2319-25. PubMed ID: 9736556
[TBL] [Abstract][Full Text] [Related]
19. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
Bethel CR; Taracila M; Shyr T; Thomson JM; Distler AM; Hujer KM; Hujer AM; Endimiani A; Papp-Wallace K; Bonnet R; Bonomo RA
Antimicrob Agents Chemother; 2011 Jul; 55(7):3465-75. PubMed ID: 21555770
[TBL] [Abstract][Full Text] [Related]
20. OHIO-1 beta-lactamase resistant to mechanism-based inactivators.
Bonomo RA; Currie-McCumber C; Shlaes DM
FEMS Microbiol Lett; 1992 Apr; 71(1):79-82. PubMed ID: 1320587
[No Abstract] [Full Text] [Related]
[Next] [New Search]
